Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening Articles uri icon

authors

  • ARENAZ CALLAO, MARIA PILAR
  • GONZÁLEZ DEL RÍO, RUBÉN
  • QUINTANA, AINHOA LUCIA
  • J. THOMPSON, CHARLES
  • MENDOZA LOSANA, ALFONSO
  • RAMÓN GARCÍA, SANTIAGO

publication date

  • January 2019

start page

  • 1

end page

  • 16

issue

  • 1, e0007126

volume

  • 13

International Standard Serial Number (ISSN)

  • 1935-2727

Electronic International Standard Serial Number (EISSN)

  • 1935-2735

abstract

  • The potential use of clinically approved beta-lactams for Buruli ulcer (BU) treatment was investigated with representative classes analyzed in vitro for activity against Mycobacterium ulcerans. Beta-lactams tested were effective alone and displayed a strong synergistic profile in combination with antibiotics currently used to treat BU, i.e. rifampicin and clarithromycin; this activity was further potentiated in the presence of the beta-lactamase inhibitor clavulanate. In addition, quadruple combinations of rifampicin, clarithromycin, clavulanate and beta-lactams resulted in multiplicative reductions in their minimal inhibitory concentration (MIC) values. The MIC of amoxicillin against a panel of clinical isolates decreased more than 200-fold within this quadruple combination. Amoxicillin/clavulanate formulations are readily available with clinical pedigree, low toxicity, and orally and pediatric available; thus, supporting its potential inclusion as a new anti-BU drug in current combination therapies.

subjects

  • Biology and Biomedicine
  • Chemistry
  • Pharmacy